JP2002504539A - ホスホリパーゼ酵素の阻害剤 - Google Patents

ホスホリパーゼ酵素の阻害剤

Info

Publication number
JP2002504539A
JP2002504539A JP2000533409A JP2000533409A JP2002504539A JP 2002504539 A JP2002504539 A JP 2002504539A JP 2000533409 A JP2000533409 A JP 2000533409A JP 2000533409 A JP2000533409 A JP 2000533409A JP 2002504539 A JP2002504539 A JP 2002504539A
Authority
JP
Japan
Prior art keywords
alkyl
methyl
phenyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000533409A
Other languages
English (en)
Japanese (ja)
Inventor
ジャスバー・エス・シーラ
ニール・カイラ
ジョン・シー・マッキュー
フランク・ラバリング
ジーン・イー・ビーミス
イービン・シアン
Original Assignee
ジェネティックス・インスチチュート・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネティックス・インスチチュート・インコーポレーテッド filed Critical ジェネティックス・インスチチュート・インコーポレーテッド
Publication of JP2002504539A publication Critical patent/JP2002504539A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2000533409A 1998-02-25 1999-02-24 ホスホリパーゼ酵素の阻害剤 Withdrawn JP2002504539A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3006298A 1998-02-25 1998-02-25
US09/030,062 1998-02-25
PCT/US1999/003899 WO1999043651A2 (fr) 1998-02-25 1999-02-24 Inhibiteurs d'enzymes phospholipases

Publications (1)

Publication Number Publication Date
JP2002504539A true JP2002504539A (ja) 2002-02-12

Family

ID=21852314

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000533409A Withdrawn JP2002504539A (ja) 1998-02-25 1999-02-24 ホスホリパーゼ酵素の阻害剤

Country Status (19)

Country Link
EP (1) EP1056719A2 (fr)
JP (1) JP2002504539A (fr)
KR (1) KR20010041343A (fr)
CN (1) CN1299347A (fr)
AU (1) AU2782699A (fr)
BG (1) BG104780A (fr)
BR (1) BR9908280A (fr)
CA (1) CA2322161A1 (fr)
EA (1) EA200000868A1 (fr)
EE (1) EE200000486A (fr)
HR (1) HRP20000552A2 (fr)
HU (1) HUP0100757A3 (fr)
ID (1) ID27280A (fr)
IL (1) IL137718A0 (fr)
NO (1) NO20004220L (fr)
PL (1) PL342995A1 (fr)
SK (1) SK12742000A3 (fr)
TR (1) TR200002446T2 (fr)
WO (1) WO1999043651A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500190A (ja) * 2003-07-25 2007-01-11 ワイス Ｃｐｌａ２阻害剤の製法
JP2008517959A (ja) * 2004-10-27 2008-05-29 エフ．ホフマン−ラ ロシュ アーゲー 新規なインドール又はベンゾイミダゾール誘導体
JP2008527029A (ja) * 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000068223A1 (fr) * 1999-05-05 2000-11-16 Aventis Pharma Limited Urees en tant que modulateurs de l'adhesion cellulaire
CA2415742A1 (fr) 2000-07-25 2002-01-31 Merck & Co., Inc. Indoles n-substitues utiles pour le traitement du diabete
KR100854424B1 (ko) 2001-01-29 2008-08-27 3-디멘져널 파마슈티칼즈 인코오포레이티드 치환된 인돌 및 인테그린 길항제로서의 이들의 용도
EP1392639B1 (fr) 2001-05-03 2008-09-17 Galileo Laboratories, Inc. Derives de pyruvates
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
ATE367812T1 (de) 2001-06-20 2007-08-15 Wyeth Corp Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1)
US7291639B2 (en) 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
JPWO2003000668A1 (ja) * 2001-06-25 2004-10-07 日本曹達株式会社 オキサ（チア）ゾリジン化合物、製造法および抗炎症薬
US7101875B2 (en) 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US6797708B2 (en) * 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US6635771B2 (en) 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
AR037684A1 (es) * 2001-12-03 2004-12-01 Wyeth Corp Compuestos benzhidrilindolico inhibidores de la fosfolipasa citosolica a2, un proceso para su preparacion, el uso de dichos compuestos para la fabricacion de medicamentos y compuestos intermediarios
EP1892239B1 (fr) * 2001-12-03 2013-02-20 Wyeth LLC Inhibitieurs de la phospholipase A2 cytosolique
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
ES2342596T3 (es) 2002-08-29 2010-07-09 MERCK SHARP & DOHME CORP. Indoles con actividad anti-diabetica.
AU2003260085B2 (en) 2002-08-29 2008-09-11 Merck & Co., Inc. Indoles having anti-diabetic activity
US7795280B2 (en) 2002-11-07 2010-09-14 N.V. Organon Indoles useful in the treatment of androgen-receptor related diseases
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CA2509191A1 (fr) 2002-12-10 2004-06-24 Wyeth Derives d'acide 1h-indol-3-yl glyoxylique a substitution aryle, aryloxy et alkyloxy en tant qu'inhibiteurs de l'inhibiteur de l'activateur du plasminogene-1 (pai-1)
WO2004052856A1 (fr) 2002-12-10 2004-06-24 Wyeth Derives d'acide indole oxo-acetyl amino acetique substitue comme inhibiteurs d'inhibiteur-1 de l'activateur du plasminogene (pai-1)
CA2509238A1 (fr) 2002-12-10 2004-06-24 Wyeth Derives substitues d'acides 3-carbonyl-1h-indol-1-yl acetique comme inhibiteurs de l'ihibiteur-1 d'activation plasminogenique
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
DE602005009209D1 (de) 2004-06-18 2008-10-02 Biolipox Ab Zur behandlung von entzündungen geeignete indole
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
WO2007024294A2 (fr) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certains urees substitues, modulateurs de l'activite des kinases
GT200600228A (es) * 2005-05-27 2006-12-26 Inhibidores de la fosfolipasa a2 citosolica
WO2007022321A2 (fr) 2005-08-17 2007-02-22 Wyeth Indoles substitues et procedes d'utilisation de ceux-ci
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
JP2011509991A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2558463A1 (fr) 2010-04-14 2013-02-20 Incyte Corporation Dérivés condensés en tant qu'inhibiteurs de i3
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
EP2655374B1 (fr) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (fr) 2011-03-25 2012-10-04 Incyte Corporation Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k
KR102371532B1 (ko) 2011-09-02 2022-03-07 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
MX349943B (es) 2012-07-17 2017-08-21 Glaxosmithkline Ip No 2 Ltd Indolcarbonitrilos como moduladores selectivos del receptor de androgeno.
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
NZ734993A (en) 2015-02-27 2024-03-22 Incyte Holdings Corp Salts of pi3k inhibitor and processes for their preparation
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
JP2022508648A (ja) 2018-10-05 2022-01-19 アンナプルナ バイオ インコーポレイテッド Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE314373B (fr) * 1966-04-12 1969-09-08 Sumitomo Chemical Co
FR1492929A (fr) * 1966-05-11 1967-08-25 Roussel Uclaf Nouveaux 1-(omega-carboxyalcoyl) indoles substitués et procédé de préparation
US3505354A (en) * 1967-05-18 1970-04-07 Geigy Chem Corp 2-methyl-3-p-halobenzoylindole-n-aliphatic acids
DE1816335A1 (de) * 1968-12-21 1970-07-09 Thiemann Gmbh Chem Pharm Fabri Verfahren zur Herstellung von [2-Methyl-5-alkoxy-3-acyl-indol-1]-essigsaeuren und deren Estern
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
AU623897B2 (en) * 1988-04-13 1992-05-28 Ici Americas Inc. Indolyl and indazolyl cyclic amides
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5290798A (en) * 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
CN1039714C (zh) * 1992-05-13 1998-09-09 森得克斯(美国)股份有限公司 取代吲哚衍生物、它的制备方法及其应用
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
DE4338770A1 (de) * 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
AU3767997A (en) * 1996-08-01 1998-02-25 Merckle Gmbh Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a2
WO1998008818A1 (fr) * 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibiteurs des enzymes phospholipases

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500190A (ja) * 2003-07-25 2007-01-11 ワイス Ｃｐｌａ２阻害剤の製法
JP2008517959A (ja) * 2004-10-27 2008-05-29 エフ．ホフマン−ラ ロシュ アーゲー 新規なインドール又はベンゾイミダゾール誘導体
JP2008527029A (ja) * 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類

Also Published As

Publication number Publication date
BR9908280A (pt) 2000-10-31
HUP0100757A1 (hu) 2001-08-28
AU2782699A (en) 1999-09-15
CN1299347A (zh) 2001-06-13
HUP0100757A3 (en) 2001-11-28
HRP20000552A2 (en) 2001-04-30
SK12742000A3 (sk) 2001-05-10
IL137718A0 (en) 2001-10-31
WO1999043651A2 (fr) 1999-09-02
EE200000486A (et) 2002-02-15
NO20004220L (no) 2000-10-05
CA2322161A1 (fr) 1999-09-02
ID27280A (id) 2001-03-22
NO20004220D0 (no) 2000-08-23
EA200000868A1 (ru) 2001-04-23
TR200002446T2 (tr) 2000-12-21
EP1056719A2 (fr) 2000-12-06
PL342995A1 (en) 2001-07-16
BG104780A (en) 2001-10-31
KR20010041343A (ko) 2001-05-15
WO1999043651A3 (fr) 1999-12-16

Similar Documents

Publication Publication Date Title
JP2002504539A (ja) ホスホリパーゼ酵素の阻害剤
US6828344B1 (en) Inhibitors of phospholipase enzymes
AU765427B2 (en) Inhibitors of phospholipase enzymes
JP2002504551A (ja) ホスホリパーゼａ２の阻害剤
US6916841B2 (en) Inhibitors of phospholipase enzymes
JP4313819B2 (ja) 治療におけるｃｒｔｈ２アンタゴニストの使用
US6500853B1 (en) Inhibitors of phospholipase enzymes
EP0832066A1 (fr) (indole-2-carbonyl-)-amides substitues en n et leurs derives, servant d'inhibiteurs de la glycogene phosphorylase
JPS63246372A (ja) ３−ヘテロ置換−ｎ−ベンジル−インドール
JP2000516958A (ja) ホスホリパーゼ酵素の阻害剤
MX2007011091A (es) Derivados de acido indol 1-acetico con actividad antagonista de pgd2.
FR2880625A1 (fr) Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
CA2576727A1 (fr) Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
JP2006516982A (ja) ホスホリパーゼａ２阻害剤としての新規ヘテロアリール置換アセトン誘導体
MXPA00008295A (en) Inhibitors of phospholipase enzymes
MXPA00008292A (en) Inhibitors of phospholipase enzymes
CZ20003115A3 (cs) Inhibitory fosfolipázy
Bach et al. 1H-indole-3-glyoxylamide SPLA 2 inhibitors
CZ20003113A3 (cs) Inhibitory fosfolipázy
CZ20003117A3 (cs) Inhibitory fosfolipázy
MXPA00008294A (en) Inhibitors of phospholipase a2

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20060509